课题基金 / 基金详情

HHV-6, HHV-7, AND IMMUNOCOMPROMISED PATIENTS

HHV-6, HHV-7, AND IMMUNOCOMPROMISED PATIENTS
HHV-6、HHV-7 和免疫功能低下的患者
批准号:
3148441
负责人:
Paul D Griffiths
金额:
$20.24万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-07-15 至 1996-06-30

项目摘要

项目成果

Paul D Griffiths的其他基金

相似基金

相关文献

中文摘要
翻译
最近发现了两种新的人类疱疹病毒。整体 该项目的目的是更好地确定其医学意义 在其他疱疹病毒重要的免疫功能低下患者中 病原体 具体目标1 从患者身上收集系列样本,并检测是否存在 HHV 6和HHV 7的定性PCR、定量PCR和分型方法 病毒株。 具体目标2 使用这些病毒学标准来定义感染患者, IgG抗体的血清学方法的特异性和灵敏度, 测定 具体目标3 分析所有获得的结果,以确定时间关联 病毒的存在与特定的临床综合征之间的关系。到 确定这些症状是否与大量病毒有关 通过定量方法检测。 为了确定预后价值, 定性或定量检测病毒的未来疾病 以预期的方式。 具体目标4 为了确定是否感染或疾病归因于任何一种病毒, 由内源性病毒再活化或初次感染获得 或在接受移植的患者中来自供体器官的再感染。 到 确定接受者中预先存在的免疫力是否可以缓解 这些病毒的潜在致病性。 总的来说,这个项目将定义这些新的医学意义, 人类疱疹病毒的免疫功能低下的患者,并将确定何时 病毒复制处于最高水平, 化疗是可以计划的。
英文摘要
Two new human herpesviruses have recently been described. The overall objective of this project is to better define their medical significance in immunocompromised patients in whom other herpesviruses are important pathogens. Specific Aim 1 To collect serial samples from the patients and test for the presence of HHV6 and HHV7 using qualitative PCR, quantitative PCR and methods to type strains of virus. Specific Aim 2 To use these virologic criteria to define infected patients so that the specificity and sensitivity of serologic methods for IgG antibodies can be determined. Specific Aim 3 To analyse all of the results obtained to identify temporal associations between the presence of either virus and particular clinical syndromes. To determine if these syndromes are associated with greater amounts of virus detected by quantitative methods. To determine the prognostic value for future disease of detecting either virus qualitatively or quantitatively in a prospective manner. Specific Aim 4 To determine whether infection or disease attributable to either virus is acquired from endogeneous reactivation of virus or from primary infection or reinfection from the donor organ in patients undergoing transplant. To determine if pre-existing immunity in the recipient can moderate the pathologic potential of these viruses. Overall, this project will define the medical significance of these new human herpesviruses for immunocompromised patients and will define when virus replication is at its highest so that trials of antiviral chemotherapy can be planned.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE
  • 批准号:
    6579263
  • 项目类别:
  • 资助金额:
    $18.9万
  • 财政年份:
    2003
  • 负责人:
    Paul D Griffiths
  • 依托单位:
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE
  • 批准号:
    6947730
  • 项目类别:
  • 资助金额:
    $18.9万
  • 财政年份:
    2003
  • 负责人:
    Paul D Griffiths
  • 依托单位:
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE
  • 批准号:
    7117606
  • 项目类别:
  • 资助金额:
    $18.46万
  • 财政年份:
    2003
  • 负责人:
    Paul D Griffiths
  • 依托单位:
PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE
  • 批准号:
    6771730
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2003
  • 负责人:
    Paul D Griffiths
  • 依托单位:
海外基金